ROCHESTER, N.Y., Nov. 15 /PRNewswire-FirstCall/ -- VirtualScopics Inc. announced today that the company has co-authored two studies that will be presented at the American College of Rheumatology Meeting in San Diego this week.
Yesterday, Monica Barbu-McInnis, an imaging scientist at VirtualScopics, presented an important osteoarthritis study entitled “Bone-Cartilage Contrast Ratio (BCCR) from MRI Dess Sequence: Signal-Based Quantitative Biomarker in OA Studies”. The presentation deals with VirtualScopics’ proprietary imaging analysis for the pharmaceutical, biotech and medical device markets. It explores bone-cartilage contrast ratio as a quantitative osteoarthritis (OA) biomarker. The results show this biomarker can be used to quantify differences between OA and normal subjects. The ability to quantitatively separate normal and OA subjects could potentially be used in clinical trials for subject selection and/or to monitor the effect of the treatment.
The second presentation entitled, “The Prevalence of Bone Marrow Edema in Sibling Pairs with Familiar Osteoarthritis at Multiple Sites: The GARP Study”, describes results from a joint research effort between VirtualScopics, Pfizer and Leiden University Medical Center in the Netherlands. The findings of that study eliminate bone marrow edema as a correlated indicator of joint pain. While bone marrow edema is not correlated to pain as shown in this research, there remains the possibility that bone marrow edema is an early indicator of OA. VirtualScopics’ image analysis tools were utilized in completing the study.
About VirtualScopics, LLC
VirtualScopics, LLC is a provider of advanced medical image analysis services. The company evolved from research first carried out at the University of Rochester Medical Center and School of Engineering. VirtualScopics has created a suite of image analysis tools used in detecting and analyzing specific structures in volumetric medical images, as well as characterizing minute changes in structures over time, providing vital information to support clinical trials and diagnostic applications. The firm’s proprietary software algorithms can assemble hundreds of separate medical images taken during an MRI session into a single, three-dimensional model, bringing a new and previously unobtainable source of data to clinical researchers. For more information about VirtualScopics, visit www.virtualscopics.com.
Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.
Contact: Tracy Bagatelle-Black Bagatelle-Black Public Relations 661/263-1842 tracy@bagatelleblack.com
VirtualScopics Inc.
CONTACT: Tracy Bagatelle-Black, Bagatelle-Black Public Relations,661-263-1842, or tracy@bagatelleblack.com
Web site: http://www.virtualscopics.com/
